China Universal Asset Management Co. Ltd. Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

China Universal Asset Management Co. Ltd. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 10.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,099 shares of the company’s stock after purchasing an additional 1,732 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $239,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Simplify Asset Management Inc. raised its stake in Syndax Pharmaceuticals by 62.5% during the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock valued at $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after acquiring an additional 208,043 shares during the last quarter. State Street Corp grew its stake in shares of Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Syndax Pharmaceuticals by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock valued at $13,397,000 after purchasing an additional 41,458 shares during the last quarter. Finally, Barclays PLC lifted its position in Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares during the period.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $14.17 on Monday. The stock has a fifty day simple moving average of $14.23 and a two-hundred day simple moving average of $17.70. The firm has a market capitalization of $1.21 billion, a PE ratio of -3.90 and a beta of 0.89. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.06 and a 52-week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the prior year, the business posted ($0.73) EPS. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. UBS Group started coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. Scotiabank lowered their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).